Themis Bioscience GmbH

Quick facts

Phase 2 pipeline

• MV-CHIK
• MV-CHIK high dose
• MV-CHIK low dose
• MV-CHIK lyophilised formulation, low dose
• MV-CHIK SPS® formulation, low dose
• V184

Phase 1 pipeline

• MV-LASV
• MV-ZIKA

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Themis Bioscience GmbH portfolio CI brief
• Themis Bioscience GmbH pipeline updates RSS